Inappropriately expressed or mutated microRNAs cause significant changes in critical biological pathways and therefore represent potential targets whose selective modulation could alter the course of disease. Pioneering studies by Regulus scientists and collaborators have demonstrated that modulating microRNAs can effectively regulate biological processes and produce therapeutically beneficial results.

Regulus is focused on advancing microRNA therapeutics across several areas, including fibrosis, hepatitis C virus (HCV) infection, immuno-inflammatory diseases, metabolic diseases, and oncology.

Regulus is utilizing established oligonucleotide technologies for a rare breakthrough in biology